Search

Search Constraints

You searched for: Author/Creator Labianca, R.

Search Results

1. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015)

2. 2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with "non diffusive type" gastric carcinoma radically resected. (September 2015)

4. Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study. Issue 164 (April 2018)

5. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. Issue 4 (July 2016)

6. LBA23FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. (18th September 2017)

7. OC-1a: A prospective study of hemostatic biomarkers to predict early recurrence in high-risk breast cancer women undergoing post-surgical adjuvant systemic therapy. Issue 151 (March 2017)

8. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (May 2021)

9. PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer. Issue 213 (May 2022)

10. PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy. Issue 200 (April 2021)